High-dose
ciclosporin markedly raises
etoposide serum levels and increases the suppression of white blood cell production. Severe
toxicity has been reported in one patient.
Some have suggested reducing the dose of
etoposide by 40 or 50%. The use of high- dose
ciclosporin for multidrug resistant tumour modulation remains experimental and should only be used in
clinical studies. Concurrent use should be very well monitored.